Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting

Acta Obstetricia et Gynecologica Scandinavica

Volumn 83, Issue 4, 2004, Pages 390-394

  Acharya, Ganesh ^a   Haugen, Michael ^a   Brathen, Anders ^a   Nilsen, Ingard ^a   Maltau, Jan Martin ^a  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Medical abortion; Mifepristone; Prostaglandin; Ultrasound

Indexed keywords

MIFEPRISTONE; PROSTAGLANDIN DERIVATIVE;

ADOLESCENT; ADULT; ASPIRATION; CURETTAGE; ECHOGRAPHY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL; REVIEW; THERAPEUTIC ABORTION; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING;

ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADOLESCENT; ADULT; ALPROSTADIL; AMBULATORY CARE FACILITIES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERUS;

EID: 1642464688     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2004.00368.x     Document Type: Review

References (17)

1. Grimes DA. Medical abortion in early pregnancy: a review of evidence. Obstet Gynecol 1997; 89: 790-6.
2. Kahn JG, Becker BJ, MacIsaa L, Amory JK, Neuhaus J, Olkin I et al. The efficacy of medical abortion: a meta-analysis. Contraception 2000; 61: 29-40.
3. Bjørge L, Johnsen SL, Midbøe G, Augestad G, Økland I, Heiland H et al. Early pregnancy termination with mifepristone and misoprostol in Norway. Acta Obstet Gynecol Scand 2001; 80: 1056-61.
4. Winikoff B, Ellertson C, Clark S. Analysis of failure in medical abortion. Contraception 1996; 54: 323-7.
5. Fielding SL, Schaff EA, Nam N. Clinicians' perception of sonogram indication for mifepristone abortion up to 63 days. Contraception 2002; 66: 27-31.
6. Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol: results of a large multicenter trial in the United States. Arch Fam Med 1998; 7: 360-6.
7. Creinin MD, VittinghoffE, Keder L, Darney PD, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception 1996; 53: 321-7.
8. Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception 1999; 59: 1-6.
9. Fonseca W, Alencar AJC, Mota FSB, Coelho HLL. Misoprostol and congenital malformations. Lancet 1991; 338: 56.
10. Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotrophin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol 2000; 183: S34-43.
11. Nyberg DA, Mack LA, Harvey D, Wang K. Value of the yolk sac in evaluating early pregnancies. J Ultrasound Med 1988; 7: 129-35.
12. Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol 2000; 183:S65-75.
13. Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Eng J Med 1998; 338: 1241-7.
14. Allen RH, Westhoff C, De Nonno L, Fielding S, Schaff EA. Curettage after mifepristone-induced abortion: frequency, timing and indications. Obstet Gynecol 2001; 98: 101-6.
15. Harwood B, Meckstroth KR, Mishell DR Jr, Jain JK. Serum beta-human chorionic gonadotrophin levels and endometrial thickness after medical abortion. Contraception 2001; 63: 255-6.
16. Luise C, Jermy K, May C, Costello G, Collins WP, Bourne TH. Outcome of expectant management of first trimester miscarriage: observational study. Br Med J 2002; 324: 873-5.
17. Walker K, Schaff E, Fielding S, Fuller L. Monitoring serum chorionic gonadotrophin levels after mifepristone abortion. Contraception 2001; 64: 271-3.